Yu JS, Chin L, Oh J, Farias J. Performance-based risk-sharing agreements for pharmaceuticals in the United States: a systematic verification. J Manag Care Spec Pharm. 2017;23(10):1028-40. The level of implementation of risk-sharing agreements in Spain has been high, with 90% of respondents saying that they currently have such a contract with a pharmaceutical company and that they want to renew it or sign new ones. Respondents noted that the most frequent risk-sharing agreements take the form of price volume. Oncology, neurology, dermatology and infectious diseases were the main medical specialties that used these agreements. Risk-sharing agreements have become a popular mechanism to offset the payers` emphasis on cost management and the need for the manufacturer to access the market for new products. In Europe, variations in these agreements are widespread and are becoming more important in the United States. However, there is a lot of confusion between payers and manufacturers about terminology. This article aims to clarify the confusion by providing general information on the emergence of risk-sharing agreements, definitions of “risk” and perspectives on the objectives of the payer and manufacturers when these agreements are concluded.
Electronic medical records systems (EMRs) are now able to marry costs with the results of care and offer doctors and other health professionals a more in-depth overview of the entire care process, including measures such as: Garattini L, Casadei G. Risk Sharing Agreements: What lessons from Italy? Int J Technol Review of Health Care. 2011;27 (2):169-72. Klemp M, Frénsdal K, Facey K, on behalf of the HTAi Policy Forum. What principles should govern the implementation of administered access agreements? Int J Technol Review of Health Care. 2011;2011(27):77–83. The questionnaire also examined the relationship between risk-sharing agreements and the promotion of personalized medicine. In this sense, participants (85%) notes that price and volume agreements would be maintained in a similar manner, regardless of the type of drug (conventional drugs or that require genetic testing to customize treatments); However, other types of agreements would be more appropriate in personalized medicine (81%). Barros PP.
The simple cost-effectiveness of risk-sharing agreements between the NHS and the pharmaceutical industry. Econ Health. 2011;20(4):461–70. The questionnaire focused on three types of agreements (price volume, efficiency payment and efficiency compensation) and asked for information on various related issues. Most responders (80%) stated that price-volume agreements were implemented in their organizations, while 20% were in full force on Payment-for-Efficacy and only one responder said it had signed a payment contract for efficiency (note that more than one type of agreement could exist in a particular center). Oncology (97%), neurology (75%), dermatology (49%) Infectious diseases (46%) These agreements were the main medical specialties, the modality of which was, in 95% of cases, the volume of prices. However, efficiency payment agreements have been concluded in most disciplines, with the exception of oncology (20%) Barely 5% of the answers. This study examined the degree of use of risk-sharing agreements in Spain and the perception of hospital pharmacists as to the relevance of several elements in their implementation. The questionnaire was distributed through the Spanish Society of Hospital Pharmacy, which has more than 3,023 members; During the investigation period, a warning was issued to encourage participation.